Sign in to fuzzto save your conversations, follow your research and come back anytime.
Fermenta Biotech
SectorHealthcare
The Quarter story
The two most recent quarterly results, compared side-by-side.
Customer base expanded and domestic sales took lead, but earnings and key segment revenues cooled after a strong Q4 peak.
High-value clients grow from 2 in Q2 FY26 to 7 in Q4 FY26, strengthening the enterprise customer base.
Earnings per share fall from ₹7.49 in Q1 FY26 to ₹3.34 in Q1 FY27, reflecting compressed profitability.
India revenue share rises from 19% in Q1 FY26 to 47% in Q1 FY27, confirming a strong domestic sales shift.
Profit after tax drops from ₹22 Cr in Q1 FY26 to ₹9.5 Cr in Q1 FY27, highlighting margin pressure.
Major clients (>5% revenue) drop from 4 in Q2 FY26 to 2 in Q4 FY26, reducing dependency on single buyers.
Green Chemistry and Enzymes revenue plunges from ₹9.8 Cr in Q1 FY26 to ₹2.3 Cr in Q1 FY27, signaling sharp segment contraction.
Mid-tier clients expand from 41 in Q2 FY26 to 68 in Q4 FY26, building a wider revenue foundation.
Consolidated revenue cools from a peak of ₹551 Cr in Q4 FY26 to ₹121.8 Cr in Q1 FY27, showing seasonal normalization.
